From first collection to commercial launch: Streamlining your supply chain to support next generation therapies

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

From first collection to commercial launch: Streamlining your supply chain to support next generation therapies

With the surge of innovative cell and gene therapies moving to market, commercial readiness is crucial to successfully delivering these therapies to waiting patients.

As your therapy operations move from early-phase clinical trials to larger populations in late-stage trials and commercialization, your supply chain complexity—and risk—increases. Anticipating common setbacks and actively planning for their solution requires a specialized and collaborative approach with your supply chain partner.

Attend this upcoming webinar for expert insights into strategies that aid in the development of a commercial supply chain for emerging autologous and allogeneic therapies.

Proven supply chain strategies that have supported the successful commercial launch of cell and gene therapies
Keys to forming and maintaining successful collaborations in cell therapy starting material procurement and management
The importance of leveraging partners that have historical expertise and offer comprehensive support across the commercial supply chain
Decisions made during clinical development to help anticipate challenges at each phase of advancement and streamline commercialization

Chris McClain

Head of Business Development & Sales at Be The Match BioTherapies

Chris McClain is the Senior Vice President of Sales and Business Development for Be The Match BioTherapies. He leads the sales and business development team, which engages with companies developing innovative, lifesaving therapies that can leverage the cell sourcing, cell therapy supply chain, CRO services, and outcomes tracking capabilities of the National Marrow Donor Program (NMDP) / Be The Match.

Before joining Be the Match BioTherapies full-time, Chris was co-Founder of Nora Therapeutics, Inc., a venture-backed biopharmaceutical company developing novel therapies in areas of significant unmet medical need in reproductive health. While at Nora Therapeutics, Chris and his team raised more than $50 million in venture capital to fund pre-clinical and clinical development of Nora’s lead asset and build out a world-class executive team. Prior to founding Nora Therapeutics, Chris held a variety of management consulting and operational roles in the technology sector.

He has served as an advisory member of the University of Minnesota Office for Technology Commercialization Venture Center, a guest lecturer in the Life Sciences program at the University of Minnesota’s Carlson Graduate School of Management, a mentor to the annual MNCup startup competition, and a co-chair of Medical Alley’s Biotech Shared Interest Group.

Chris has an MBA and B.A. in Economics from the University of California, Berkeley.